학술논문

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Document Type
Article
Source
Infection; Oct2023, Vol. 51 Issue 5, p1273-1284, 12p, 1 Diagram, 4 Charts, 5 Graphs
Subject
DISEASE progression
DRUG efficacy
STATISTICS
CAUSES of death
COVID-19
SARS-CoV-2
CONFIDENCE intervals
IMMUNOCOMPROMISED patients
RNA
AMINES
TREATMENT effectiveness
COMPARATIVE studies
HOSPITAL care
DESCRIPTIVE statistics
RESEARCH funding
DATA analysis
DRUG side effects
PATIENT safety
Language
ISSN
03008126
Abstract
Copyright of Infection is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)